Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 13/20 | 0.45 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097225 | 0.89 | KDM4E (0.47) | PTGESPPARGPPARAGAARAB9A | |
| SCHEMBL4921606 | 0.87 | PTGES (0.61) | PTGESPPARGPPARA | |
| SCHEMBL4095050 | 0.86 | PTGES (0.48) | PTGESPPARGPPARA | |
| SCHEMBL4228522 | 0.84 | PTGES (0.59) | PTGES | |
| SCHEMBL4089140 | 0.83 | PPARG (0.46) | PTGESPPARGPPARAMAPT | |
| SCHEMBL4923306 | 0.82 | PTGES (0.52) | PTGES | |
| SCHEMBL4090259 | 0.80 | PTGES (0.61) | PTGES | |
| SCHEMBL4089205 | 0.80 | PTGES (0.56) | PTGESPPARGPPARAMAPT | |
| Water SCHEMBL4923346 | 0.78 | PTGES (0.66) | PTGESPPARGPPARAGAA | |
| Water SCHEMBL4923358 | 0.78 | PTGES (0.66) | PTGESPPARGPPARAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | PYCR1, ARG2, ARG1 | PTGES 47/4885PPARG 1316/4885PPARA 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.